“Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient Treated with a Novel Combination Treatment with Anti PDL1 Antibody (Durvalumab) and VEGFR2 Antibody (Ramucirumab)”, acmcr, vol. 4, no. 1, pp. 8–14, Jan. 2020, Accessed: Sep. 11, 2026. Available: https://fortunejournals.org/ojs/index.php/acmcr/article/view/22266